|
|
|
06.08.25 - 13:30
|
Japan OKs Price Cut for Alzheimer′s Drug Lecanemab (Nippon)
|
|
|
Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and U.S. industry peer Biogen Inc., by 15 pct in Japan starting Nov. 1. The decision is based on an assessment by the Central Social Insurance Medical Council that cited the low cost-effectiveness of the drug us......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.25 - 22:06
|
Sage Therapeutics Announces Second Quarter 2025 Financial Results (Business Wire)
|
|
|
Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter
Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025
Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025.
“Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “As we work with Supernus to complete the transaction, we take pride in the progress made to date and remain focused on the important work of he...
|
|
|
30.07.25 - 17:03
|
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer′s Association International Conference (AAIC) 2025 (PR Newswire)
|
|
|
TOKYO and CAMBRIDGE, Mass., July 30, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the two-year......
|
|
|
30.07.25 - 17:03
|
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer′s Association International Conference (AAIC) 2025 (GlobeNewswire EN)
|
|
|
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
